MRNA Stock Outstanding Shares
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
Market Insider MRNA
Investors cannot turn a blind eye to insiders as well as institutional ownership. They need to follow insider trades to determine the direction the stock is likely to take.
Institutional Ownership
About 71.68% of MRNA shares are held by financial institutions. WELLINGTON MANAGEMENT GROUP LLP is the top corporate investor, holding 5.6M shares valued at $597.24M. A 1.47% stake in Moderna, Inc. is owned by the company. RHUMBLINE ADVISERS owns 588.89K shares valued at $62.75M, which translates its holding of 0.15% of the stake in the company.
MRNA Insiders
Among the MRNA insiders holding of 9.52% of the stake in company, BANCEL STEPHANE, Chief Executive Officer, holds the largest shares of 5.46M. AFEYAN NOUBAR, director, is the second largest MRNA insider with ownership of 2.22M shares. HOGE STEPHEN, President, stands third with possession of 1.44M shares of that stake.
Buying/Selling by Insiders
Insider Transaction Summary (6 Months)
Frequently Asked Questions
A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own MRNA shares is 1176, representing 71.68% of the company's common stock.
WELLINGTON MANAGEMENT GROUP LLP, in the last quarter, reduced its stake in MRNA by -22.43% restricting it's holding to 5.6 million shares of worth nearly $597.24M. CREDIT SUISSE AG/ also lessened -36.68% of the MRNA shares from its portfolio, reducing its holding to 539.49 thousand shares of worth $57.49M. BANK OF MONTREAL /CAN/ also shunned MRNA shares holding by -18.4% last quarter which brought its holding to 488.11 thousand shares worth $53.99M.
As per its latest 13F filing, RHUMBLINE ADVISERS increased its stake in MRNA by 0.82% in the last quarter. The institutional holder raised its holding to 588.89 thousand shares having worth more than $62.75M. KBC GROUP NV also added 780.99% more shares of MRNA to its portfolio, raising its holding to 519.53 thousand shares of worth $55.36M. MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. also increased its MRNA shares holding by 15.45% which brought its holding to 446.47 thousand shares worth $47.58M.
The insider with the most stakes in MRNA is Bancel Stephane , Chief Executive Officer at the company. Additionally, MRNA stock is highly held by director AFEYAN NOUBAR and President Hoge Stephen among others.
Company executives, directors, and other insiders own 9.52% percent of Moderna, Inc.'s stock. Within the last six months, there have been 16 transaction(s) in which MRNA insiders have sold stock, totaling 9.32K shares. Insiders that have sold shares include KLINGER SHANNON THYME, HOGE STEPHEN, and MOCK JAMES M.
There have been 0 transaction(s) during the past 6-months in which Moderna, Inc. insiders have bought stock, totalling 0 shares
Around 7.38M Moderna, Inc. shares are held by insiders, which represents about 9.52% of MRNA stock.
MRNA Chief Executive Officer, Bancel Stephane holds the largest portfolio of the company's shares. MRNA shares owned by Bancel total nearly 5.46 million.
WELLINGTON MANAGEMENT GROUP LLP is the largest institutional owner in MRNA which holds 5.6 million shares worth $597.24M or 1.47% of the total MRNA shares outstanding followed by RHUMBLINE ADVISERS with ownership of 588.89 thousand shares representing 0.15% of the MRNA ownership. CREDIT SUISSE AG/ is the third largest stakeholder with 539.49 thousand shares or 0.14% of the ownership worth more than $57.49M.
Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the MRNA is concerned, it is a stock which is optionable.
Number of MRNA shares short is 43.01M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.
As of today, 384.82M shares of MRNA are outstanding.
Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, MRNA has 347.53M shares in float.
Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for MRNA is 4.04.